Evidence map›Paper›PMID 36529829›Full record

ArticleHealth & justice2022

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study.

Elizabeth C Saunders, Milan F Satcher, Laura B Monico, Ryan D McDonald, Sandra A Springer, David Farabee, Jan Gryczynski, Amesika Nyaku, Donald Reeves, Lynn E Kunkel and 5 more

Open access · goldAbstract read
In one paragraph

Article in Health & justice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Elizabeth C SaundersCenter for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, 46 Centerra Parkway, Suite 315, Lebanon, NH, 03766, USA. elizabeth.c.saunders@dartmouth.edu.ORCID http://orcid.org/0000-0002-2728-0001
Milan F SatcherDepartment of Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Laura B MonicoFriends Research Institute, Baltimore, MD, USA.
Ryan D McDonaldNew York University Grossman School of Medicine, New York, NY, USA.
Sandra A SpringerDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA.
David FarabeeNew York University Grossman School of Medicine, New York, NY, USA.
Jan GryczynskiFriends Research Institute, Baltimore, MD, USA.
Amesika NyakuDivision of Infectious Diseases, Rutgers New Jersey Medical School, New Brunswick, NJ, USA.
Donald ReevesRutgers University Correctional Health Care, Rutgers-Robert Wood Johnson Medical School, Trenton, NJ, USA.
Lynn E KunkelOregon Health and Science University -Portland State University School of Public Health and Addiction Medicine Section, Division of General Internal Medicine & Geriatrics, Oregon Health and Science University, Portland, OR, USA.
Alysse M SchultheisDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA.
Robert P SchwartzFriends Research Institute, Baltimore, MD, USA.
Joshua D LeeNew York University Grossman School of Medicine, New York, NY, USA.
Lisa A MarschCenter for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, 46 Centerra Parkway, Suite 315, Lebanon, NH, 03766, USA.
Elizabeth Needham WaddellOregon Health and Science University -Portland State University School of Public Health and Addiction Medicine Section, Division of General Internal Medicine & Geriatrics, Oregon Health and Science University, Portland, OR, USA.
Friends Research Institute · USNew York University · USDartmouth College · USPortland State University · USRutgers, The State University of New Jersey · USYale University · USDartmouth–Hitchcock Medical Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Treatment Development & Evaluation CoreP30DA029926 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2011 to 2026
$21.5M
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adultsU01DA047982 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI FARABEE, DAVID J, GRYCZYNSKI, JAN · 2019 to 2024
$20.3M
The Lifespan/Brown Criminal Justice Research Program on Substance Use and HIVR25DA037190 · NIDA · MIRIAM HOSPITAL · PI CURT G BECKWITH · 2014 to 2026
$3.5M
NCATS NIH HHS UL1 TR001863NCIPC CDC HHS R01 CE003008NIDA NIH HHS P30 DA029926NIDA NIH HHS R25 DA037190NIDA NIH HHS U01 DA047982NIDA NIH HHS U01-DA047982
6 · The paper itself

Abstract

While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed protocols to sustain healthcare delivery while reducing risk of COVID-19 transmission. This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. In December 2020, carceral sites (n = 6; median pre-COVID 2020 monthly census = 3468 people) and CTPs (n = 7; median pre-COVID 2020 monthly census = 550 patients) participating in EXIT-CJS completed a cross-sectional web-based survey. The survey assessed changes pre- (January-March 2020) and post- (April-September 2020) COVID-19 in OUD treatment, telemedicine use, re-entry supports and referral practices. Compared to January-March 2020, half of carceral sites (n = 3) increased the total number of persons initiating medication for opioid use disorder (MOUD) from April-September 2020, while a third (n = 2) decreased the number of persons initiated. Most CTPs (n = 4) reported a decrease in the number of new admissions from April-September 2020, with two programs stopping or pausing MOUD programs due to COVID-19. All carceral sites with pre-COVID telemedicine use (n = 5) increased or maintained telemedicine use, and all CTPs providing MOUD (n = 6) increased telemedicine use. While expansion of telemedicine services supported MOUD service delivery, the majority of sites experienced challenges providing community support post-release, including referrals to housing, employment, and transportation services. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to continue delivery of treatment for OUD. Expansion of telemedicine services was critical to support MOUD service delivery. Despite these innovations, sites experienced challenges providing reintegration supports for persons in the community. Pre-COVID strategies for identifying and engaging individuals while incarcerated may be less effective since the pandemic. In addition to expanding research on the most effective telemedicine practices for carceral settings, research exploring strategies to expand housing and employment support during reintegration are critical.

Indexed as

BuprenorphineCarceral settingsCOVID-19Medication for opioid use disorder (MOUD)NaltrexoneOpioid use disorder

Identifiers

PMID36529829
PMCPMC9760540
OpenAlexW4312114141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.